Moderna, Inc.
For the period ended Dec 31, 2025. Filed Feb 20, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 20, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of the Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MODERNA, INC. | ||
| Date: | By: | /s/ Stéphane Bancel |
|---|---|---|
| Stéphane Bancel | ||
| Chief Executive Officer and Director | ||
POWER OF ATTORNEY AND SIGNATURES
Each individual whose signature appears below hereby constitutes and appoints each of Stéphane Bancel and James M. Mock as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Stéphane Bancel | Chief Executive Officer and Director (Principal Executive Officer) | February 20, 2026 |
| Stéphane Bancel | ||
| /s/ James M. Mock | Chief Financial Officer(Principal Financial Officer and Principal Accounting Officer) | February 20, 2026 |
| James M. Mock | ||
| /s/ Noubar B. Afeyan, Ph.D. | Chairman and Director | February 20, 2026 |
| Noubar B. Afeyan, Ph.D. | ||
| /s/ Sandra Horning, M.D. | Director | February 20, 2026 |
| Sandra Horning, M.D. | ||
| /s/ Abbas Hussain | Director | February 20, 2026 |
| Abbas Hussain | ||
| /s/ Elizabeth Nabel, M.D. | Director | February 20, 2026 |
| Elizabeth Nabel, M.D. | ||
| /s/ Francois Nader, M.D. | Director | February 20, 2026 |
| Francois Nader M.D. | ||
| /s/ David M. Rubenstein | Director | February 20, 2026 |
| David M. Rubenstein | ||
| /s/ Paul Sagan | Director | February 20, 2026 |
| Paul Sagan | ||
| /s/ Elizabeth Tallett | Director | February 20, 2026 |
| Elizabeth Tallett | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.